Financhill
Sell
28

KRRO Quote, Financials, Valuation and Earnings

Last price:
$7.06
Seasonality move :
-18.03%
Day range:
$6.73 - $7.24
52-week range:
$5.20 - $55.89
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.94x
P/B ratio:
0.67x
Volume:
602.1K
Avg. volume:
818.6K
1-year change:
-82.06%
Market cap:
$66.1M
Revenue:
$2.3M
EPS (TTM):
-$9.42

Analysts' Opinion

  • Consensus Rating
    Korro Bio, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $93.88, Korro Bio, Inc. has an estimated upside of 516.1% from its current price of $7.02.
  • Price Target Downside
    According to analysts, the lowest downside price target is $25.00 representing 100% downside risk from its current price of $7.02.

Fair Value

  • According to the consensus of 6 analysts, Korro Bio, Inc. has 516.1% upside to fair value with a price target of $93.88 per share.

KRRO vs. S&P 500

  • Over the past 5 trading days, Korro Bio, Inc. has overperformed the S&P 500 by 22.78% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Korro Bio, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Korro Bio, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Korro Bio, Inc. reported revenues of $1.1M.

Earnings Growth

  • Korro Bio, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Korro Bio, Inc. reported earnings per share of -$1.92.
Enterprise value:
17.3M
EV / Invested capital:
--
Price / LTM sales:
8.94x
EV / EBIT:
--
EV / Revenue:
2.35x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.25x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$2.5M
Return On Assets:
-43.6%
Net Income Margin (TTM):
-1199.53%
Return On Equity:
-63.78%
Return On Invested Capital:
-48.36%
Operating Margin:
-1764.86%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue -- -- $7.4M -- $1.1M
Gross Profit -$3.9M -$4.1M $2.5M -$865K -$110K
Operating Income -$76.6M -$108.4M -$94.5M -$23.3M -$19.2M
EBITDA -$72.7M -$104.3M -$89.6M -$22.4M -$18M
Diluted EPS -$225.73 -$12.02 -$9.42 -$2.26 -$1.92
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $149.9M $101M $42.5M $152.8M $98.2M
Total Assets $202.2M $136M $46.3M $243.5M $161.6M
Current Liabilities $10.5M $20M $9.6M $13.6M $14.6M
Total Liabilities $55.1M $54M $9.6M $63.9M $62.5M
Total Equity $147.1M $82M $36.7M $179.6M $99M
Total Debt $46M $42.3M -- $41.8M $41.5M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations -$57.2M -$73.7M -$68.4M -$16.1M -$17.2M
Cash From Investing $17.3M -$122.2M $26.3M -$12.6M $7.6M
Cash From Financing $42.9M $213M $1.2M $728K $128K
Free Cash Flow -$68.6M -$91.8M -$70.2M -$21M -$17.4M
KRRO
Sector
Market Cap
$66.1M
$28.5M
Price % of 52-Week High
12.56%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-0.55%
-1.33%
1-Year Price Total Return
-82.06%
-20.32%
Beta (5-Year)
3.030
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $5.94
200-day SMA
Sell
Level $21.43
Bollinger Bands (100)
Sell
Level 12.66 - 40.06
Chaikin Money Flow
Sell
Level -5.8M
20-day SMA
Sell
Level $11.38
Relative Strength Index (RSI14)
Sell
Level 27.09
ADX Line
Sell
Level 41.68
Williams %R
Sell
Level -10.8076
50-day SMA
Sell
Level $29.84
MACD (12, 26)
Sell
Level -6.99
25-day Aroon Oscillator
Sell
Level -84
On Balance Volume
Sell
Level -5M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (0.8921)
Sell
CA Score (Annual)
Level (-1.2216)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (2.3688)
Buy
Piotroski F Score (Annual)
Level (6)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (2)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Stock Forecast FAQ

In the current month, KRRO has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KRRO average analyst price target in the past 3 months is $93.88.

  • Where Will Korro Bio, Inc. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Korro Bio, Inc. share price will rise to $93.88 per share over the next 12 months.

  • What Do Analysts Say About Korro Bio, Inc.?

    Analysts are divided on their view about Korro Bio, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Korro Bio, Inc. is a Sell and believe this share price will drop from its current level to $25.00.

  • What Is Korro Bio, Inc.'s Price Target?

    The price target for Korro Bio, Inc. over the next 1-year time period is forecast to be $93.88 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is KRRO A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Korro Bio, Inc. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of KRRO?

    You can purchase shares of Korro Bio, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Korro Bio, Inc. shares.

  • What Is The Korro Bio, Inc. Share Price Today?

    Korro Bio, Inc. was last trading at $7.06 per share. This represents the most recent stock quote for Korro Bio, Inc.. Yesterday, Korro Bio, Inc. closed at $7.02 per share.

  • How To Buy Korro Bio, Inc. Stock Online?

    In order to purchase Korro Bio, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Robinhood Win AI Investing?
Will Robinhood Win AI Investing?

Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…

Is Amazon an AI Stock?
Is Amazon an AI Stock?

With the market starting to look skittish on pure-play AI…

Google Vs NVIDIA Stock: Which Is Best?
Google Vs NVIDIA Stock: Which Is Best?

Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $4.4T
P/E Ratio: 62x

Buy
56
Is AAPL Stock a Buy?

Market Cap: $4.1T
P/E Ratio: 37x

Buy
81
Is GOOG Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 40x

Alerts

Buy
56
SMX alert for Dec 6

SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.

Buy
62
PRAX alert for Dec 6

Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.

Sell
13
PSN alert for Dec 6

Parsons Corp. [PSN] is down 21.1% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock